Posters

 

2019

January

McMeekin N, Briggs A, Wu O. A methodological framework for developing conceptual models‌ in economic evaluation. HESG Winter 2019. York, England.

May

Briggs A. Conceptualising a Framework for Modeling Systematic Lupus Erythematosus. ISPOR 2019. New Orleans Ernest N. Morial Convention Center. Louisiana, USA.

Briggs A. Developing a Mapping Function to the SQ Tree Sublingual Immunotherapy (Slit-Tablet) Trial from a SQ Grass Slit-Tablet Trial. ISPOR 2019. New Orleans Ernest N. Morial Convention Center. Louisiana, USA.

Briggs A. Estimating Quality-Adjusted Life Years (Qalys) Through Quality-Adjusted Time Without Symptoms or Toxicity (Qtwist) In Rcts: An Alternative to Economic Modelling’, ISPOR 2019, New Orleans Ernest N. Morial Convention Center, Louisiana, USA.

Briggs A. Comparison of Lost Productivity Due to Eculizumab and Ravulizumab Treatments for Paroxysmal Nocturnal Hemoglobinuria in the United States. ISPOR 2019. New Orleans Ernest N. Morial Convention Center. Louisiana, USA.

September

Manca F & Boyd K. Novel HCV Screening Strategies  for Hard to Reach Populations: Are they Cost-Effective? INHSU Conference. Montreal, Canada.

October

Bouttell J, Hawkins N & Briggs A. Test and treat threshold plot: developing a simple tool to estimate required test performance for developers of tests for treatment response. Glasgow Molecular Pathology Node Annual Symposium. Teaching and Learning Centre, Queen Elizabeth University Hospital. Glasgow, UK.

2018

June

Geue C, Hawkins N, A Bayesian Approach to Explore and Improve Methodologies for the Identification and Estimation of Subgroup Effects in Clinical Trials. SMDM 2018, Leiden‌

Baba C, Briggs A, McIntosh E,  Informing the Design of a New Preference Weighted Value Framework for Oncology: A Mixed Methods Approach SMDM 2018, Leiden

  

2017

November 

Baba C., Briggs A., McIntosh E. Identifying attributes of cancer treatments : What do stakeholders consider? ISPOR 20th Annual European Congress, Glasgow, UK. November 2017

Baba C., Grieve E., McIntosh E. An economic evaluation of 'delivering assisted lifestyles at scale' (dallas). ISPOR 20th Annual European Congress, Glasgow, UK. November 2017.

Bouttell J., Briggs A., Hawkins N. Identifying cost-effective methods of health technology assessment for developers. ISPOR 20th Annual European Congress, Glasgow, UK. November 2017.

Bouttell J., Lewsey, J.Synthetic Control Methodology  guide to the method and case study. Lancet Public Health Science Conference, London, UK. November 2017.

Briggs A. Cost-effectiveness of Nivolumab (NIVO) combined with Ipilimumab (IPI) compared with NIVO and IPI monotherapies in the first-line treatment of advanced melanoma in the United States: analysis using 28-month overall survival (OS) data from checkmate 067. ISPOR 20th Annual European Congress, Glasgow, UK. November 2017. 

Briggs A. The validity of objective response rate as a surrogate for progression-free and overall survival in the evaluation of first-line chemotherapy for advanced non-small cell lung cancer. ISPOR 20th Annual European Congress, Glasgow, UK. November 2017. 

Briggs A. Economic evaluation of single inhaler triple therapy for patients with chronic obstructive pulmonary disease (COPD) using the Galaxy model. ISPOR 20th Annual European Congress, Glasgow, UK. November 2017. 

Briggs A. A conceptual model of the economics of visualization in diagnostics and surgery. ISPOR 20th Annual European Congress, Glasgow, UK. November 2017.

Briggs A., Baba C., McIntosh E. But will they trade health? Developing an economic value framework for oncology Developing an economic value framework for oncology.ISPOR 20th Annual European Congress, Glasgow, UK. November 2017. 

Heggie R. How should we test for pre-term labour? An IPD meta-analysis and economic model. ISPOR 20th Annual European Congress, Glasgow, UK. November 2017.

Heggie R., Wu O. Cost-effectiveness of mechanical thrombectomy compared with standard treatment‌ in patients with acute ischaemic strokeISPOR 20th Annual European Congress, Glasgow, UK. November 2017.

Kohli-Lynch CN. Long-term benefits of LDL cholesterol lowering in young adulthood: A computer simulation study. ISPOR 20th Annual European Congress, Glasgow, UK. November 2017.

Kohli-Lynch CN. Cost-effectiveness of statin prioritisation based on absolute risk reduction for primary prevention of cardiovascular disease.  ISPOR 20th Annual European Congress Glasgow, UK. November 2017.

Lewsey J., Bouttell J. Investigating age-period-cohort effects using Lexis diagrams and intrinsic estimator regression modelling to understand Scotland’s ‘excess mortality’. Lancet Public Health Science Conference, London, UK. November 2017.

McIntosh E. The economics of assets in public health. University of Glasgow Capabilities Group, Glasgow, UK. November 2017.

McIntosh E. Workshop: Editorial support to the 6th book in the OUP series of Handbooks in Health Economics. Brocher Foundation, Lake Geneva, Switzerland. November 2017.

McMeekin N. Briggs A., Wu O.DDeveloping a conceptual modelling framework for economic evaluation. ISPOR 20th Annual European Congress, Glasgow, UK. November 2017.

Rezaei Hemami M., Boyd K. Cost-effectiveness of intelligent Liver Function test(iLFT) for investigation of patients with abnormal liver function tests. ISPOR 20th Annual European Congress, Glasgow, UK. November 2017.

Ryan C., Wu O. Capturing patient perspectives in the evaluation of medical devices: the case of central venous access devices in chemotherapy. ISPOR 20th Annual European Congress, Glasgow, UK. November 2017.*

Xin Y., Lewsey J., McIntosh E. Too broad to be sensitive? Exploring the responsiveness of the ICECAP-O capability wellbeing measure compared to the EQ-5D-3L to the change of clinical and QoL aspects in people with Parkinson’s. ISPOR 20th Annual European Congress, Glasgow, UK. November 2017.

 

  

2016

Wu O, McMeekin N, Hawkins N.  Lost in Translation: randomised controlled trial and systematic review evidence of intracoronary vs intravenous abciximab in ST-elevation myocardial infarcion.  ISPOR 2016, Vienna.

Ciminata G, Geue C, Wu O, Langhorne P.  The prescribing, inpatient, outpatient and Social care costs associated with atrial fibrillation in Scotland

 

2015

Boyd, K.A., McIntosh, E.,   Cost-effective management of bronchiolitis in infants : 90% versus 94% oxygen saturation, European Respiratory Society International Congress  September 2015,  Amsterdam, 


Presentations

2019

January

McMeekin N. A methodological framework for developing conceptual models in economic evaluation. HESG Winter conference. York, UK. 

Boyd K, Heggie R. Quantitative fibronectin to help decision making in women with symptoms of preterm labour: QUIDS study. Edinburgh training & Conference Venue.

 

February

Boyd K. Health Economic Considerations for Evaluating Secure Care in Scotland. Stirling University, Court Hotel.

 

April

Boyd K. iLFT project nominated in the digital innovation category. British Medical Association for BMJ Awards 2019. London, UK.

 

May

Briggs A. Gazing into The Heor Crystal Ball: What Might Be the Future Directions for Heor In The 2020'ies?. ISPOR 2019. New Orleans Ernest N. Morial Convention Center, Louisiana, USA.

Bouttell J. The Ethics and Practice of Disinvestment: On Knowing What Not to do in Health and Social Care. Kings College. London.

Venson R, Boyd K. IVF/ICSI in NHS Scotland: Cost Analysis and Setting a Tariff’, British Medical Association, National Infertility Group. Edinburgh, Scotland.

Wu O, Hsuan Hsieh P. Evidence Synthesis - A Powerful Tool That Needs to Be Handled with Care. National Defence Medical Centre (NMDC). Taipei, Taiwan.

Wu O, Hsuan Hsieh P. Adding ‘Value’ To Evidence-Based Medicine: The Role of Health Economics. Tri-Service General Hospital (TSGH). Taipe, Taiwan.

Wu O, Hsuan Hsieh P. Evidence Synthesis - A Powerful Tool That Needs to Be Handled with Care. Taipei Medical University (TMU). Taipei, Taiwan.

 

June

Hsuan Hsieh P, Wu O, McIntosh E, Geue C. Impact of Biologics on Rheumatoid Arthritis: How Have Costs Evolved? HTAi. The Maratim Hotel. Cologne, Germany.

Briggs A. The Value of Health Technology Assessment: A Mixed Methods Framework. HTAi. The Maratim Hotel. Cologne, Germany.

Germeni E. Updated Qualitative Syntheses: What Can They Offer to HTA? HTAi. The Maratim Hotel. Cologne, Germany. 

Geue C. Addressing Uncertainty Around the Reach and Quality of Optometrist Independent Prescribing in Scotland. Scottish Government. Edinburgh, Scotland.

Grieve E, Briggs A. The Value of Health Technology Assessment: A Realist Synthesis. HTAi. Cologne, Germany. 

Grieve E, Briggs A. The Value of Health Technology Assessment: A Mixed Methods Framework. HTAi. Cologne, Germany.

 

July

Robles-Zurita J. Estimating the causal effect of treatment: using randomisation as an instrumental variable. HESG. 3 July 2019.

Heggie R. Should health economists care about implementation? HESG. University of East Anglia. Norwic, UK.

Boyd K A. Health Economic Analysis & Modelling Plans: To HEAP or not to HEAP? Why should we bother? HESG. University of East Anglia. Norwich, UK. 

Manca F. Should we still be screening for HCV in Scotland and the UK? HESG. University of East Anglia. Norwich, UK.

 

September 

Geue C & Hawkins N. Improving transparency about “power” and trade-offs in subgroup selection: assessing criteria and statistical models for subgroup selection. Royal Statistical Society Conference. London, UK. 

Manca F & Boyd K. Novel HCV Screenings Strategies for Hard to Reach Populations: Are They Cost-Effective?. INHSU 2019. Montreal, Canada.

Venson R & Boyd K. Presentation of results to the National Infertility Group Meeting, Royal College of Surgeons. Edinburgh, Scotland.

Boyd K A. Including Economic Evaluation in Clinical Psychology Research. Queen Elizabeth Teaching & Learning Centre. Clinical Psychology Research Conference. Glasgow, UK.

 

October

Anopa Y. Economic evaluation of the Protecting Teeth @ 3 randomised controlled trial. Dundee Dental Education Centre. Scottish Oral Health Research Collaboration Conference. Dundee, Scotland.

Anopa Y. Economic Burden of Childhood Caries: Cost analysis of a national nursery toothbrushing programme. Scottish Health Economics (Launch Conference). Dundee, Scotland.

Wu O. Economic impact of chronic diseases and the contribution of health policies: Two reflections from the same mirror? EULAR World Arthritis Day Conference. Thon EU Hotel. Brussels, Belgium. 

Germeni E. Updating a meta-ethnography of primary care professionals’ experience of antibiotic prescribing: Key considerations and lessons learnt. University of Lugano. Lugano, Switzerland.

Bouttell J. Test and treat threshold plot: developing a simple tool to estimate required test performance for developers of tests for treatment response. Glasgow Molecular Pathology Node Annual Symposium. Teaching and Learning Centre, Queen Elizabeth University Hospital. Glasgow, UK.

 

November

Ciminata G. Comparison of propensity score methods: a case study of direct oral anticoagulants. ISPOR. Copenhagen, Denmark.

Wu O. ISPOR Women in Health Economics and Outcomes Research Initiative – Unleashing the Leader Within You. ISPOR. Copenhagen, Denmark.

Wu O. Where are we going with treatment costs in myeloma? UK Myeloma Autumn Forum. London, UK.

Wu O. Evidence for HTA: Friend or Foe? Mahidol University. Bangkok, Thailand.

Boyd K A. Presentation of Economic Review. Scottish Medicines Consortium’, New Drugs committee meeting, Glasgow, UK. National Infertility Group. 26 November 2019.

Boyd K A & Venson R. Presentation of results in the National Infertility Group Meeting. Edinburgh, UK.

 

2018

October 

Boutell J. Test and treatment threshold plot: developing a simple tool to estimate required test performance for developers of tests for treatment response. Methods for the economic evaluation of diagnostics (MEED) research forum. Leeds, UK.

Germeni E. Updating a meta-ethnography on primary care antibiotic prescribing: Key considerations and lessons learnt. 24th Annual Qualitative Health Research (QHR) Conference. Halifax, Canada.

Geue C. Costs of Prevalent and Incident Cardiovascular Disease in Patients with Type 2 Diabetes Mellitus in Scotland using Routinely Collected Data. Mount Hood Diabetes Challenge, Berlin, Germany. 

Hagpanahan H. Are tobacco control mass media campaigns effective and cost-effective? A population level analysis in Scotland. Priorities 2018: 12th International Society on Priorities in Health (ISPH). Linkoping, Sweden. 

LewseyJ., Geue C. Developing a Scottish T2DM Policy Model and a web-based decision aid “dashboard.  Mount Hood Diabetes Challenge, Dusseldorf, Germany.

 

September 


Boutell J. Review of colorectal cancer service change – introduction of universal KRAS/NRAS/BRAF testing. Glasgow Molecular Pathology Node Annual Symposium, Glasgow, UK. 

Germeni, E. Tackling inappropriate antibiotic prescribing for ARTIs in primary care: What can we learn from published qualitative research? Tackling inappropriate antibiotic prescribing for ARTIs in primary care: What can we learn from published qualitative research. 16th International Conference on Communication in Healthcare (ICCH, Porto, Portugal. 

Hsieh P. The evolving drug expenses and healthcare cost of rheumatoid arthritis: a systematic review. 78th International Pharmaceutical Federation (FIP) World Congress, Glasgow, UK.  

Hsieh P. The evolving cost of illness of rheumatoid arthritis: a systematic review.  8th ISPOR Asia Pacific Conference, Tokyo, Japan.  2018

Lewsey J., Haghpanahan H., Sim M. Disseminated quantitative drink drive evaluation results to key stakeholders. Edinburgh, UK. 

 

July

Boyd K. Economic Evaluation in Public Health and Complex Interventions: UK & European Perspectives Thai Health Promotion Foundation Conference, Bangkok, Thailand  

Haghpanan H.  Are Tobacco Control Mass Media Campaigns Effective and Cost-effective?  A population level analysis. EuHEA 2018,  Maastricht

McMeekin NDeveloping a conceptual modelling framework for economic evaluation =, EuHEA 2018,  Maastricht, Netherlands

Deidda M. Methodological challenges conducting economic evaluations alongside natural experiments: the Healthy Start Voucher case study, EUHEA 2018, Maastricht, Netherlands.

Robles Zurito, Jose-Antonio. From normal to overweight without noticing: a relative plausible explanation. EUHEA 2018, Maastricht

Robles Zurito, Jose-Antonio. Economic evaluation of culprit lesion only PCI versus immediate multivessel PCI in acute myocardial infarction complicated by cardiogenic shock: the CULPRIT-SHOCK trial. EuHEA 2018,  Maastricht, Netherlands.

 

May

Wu O.  Health Technology Assessment of Alternative and Traditional Medicines  HTAsialink, Bangkok, Thailand

 

2017 

Bouttell JLaboratory Medicine Grand Rounds Queen Elizabeth University Hospital, Glasgow UK. November 2017

Briggs A. Educational symposium: Practical implications of value-based pricing and emerging value frameworks in health technology assessment. ISPOR 20th Annual European Congress, Glasgow, UK.

Briggs A. Workshop:Determining the value of long-term outcomes associated with immuno-oncology therapies- challenges and approaches for OS extrapolations. ISPOR 20th Annual European Congress, Glasgow, UK. N

Haghpanahan H., Boyd K., McIntosh E.Effectiveness and Cost effectiveness of Tobacco Control Mass Media Campaigns ISPOR 20th Annual European Congress, Glasgow, UK. 

Kohli-Lynch CN.  A framework for the cost-effectiveness analysis of novel biomarker testing in cardiovascular disease. ISPOR 20th Annual European Congress, Glasgow, UK. 

Lewsey J., Bouttell J. Investigating age-period-cohort effects using Lexis diagrams and intrinsic estimator regression modelling to understand Scotland’s ‘excess mortality’. Lancet Public Health Science Conference, London, UK. 

McIntosh E. The economics of assets in public health. University of Glasgow Capabilities Group, Glasgow, UK. 

McIntosh E. Workshop: Editorial support to the 6th book in the OUP series of Handbooks in Health Economics. Brocher Foundation, Lake Geneva, Switzerland.